Drug Profile
MSI 753
Latest Information Update: 14 Aug 2007
Price :
$50
*
At a glance
- Originator Genaera Corporation
- Class Antifungals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 10 Jun 1997 No-Development-Reported for Mycoses in USA (Unknown route)
- 29 Nov 1995 New profile
- 29 Nov 1995 Preclinical development for Mycoses in USA (Unknown route)